Application of CD19-CAR T Cells in Refractory Relapsed Acute B Lymphocyte Leukemia / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1604-1609, 2018.
Artigo
em Chinês
| WPRIM
| ID: wpr-773049
ABSTRACT
OBJECTIVE@#To investigate the efficacy of CD19-targeted chimeric antigen receptor T-cell (CD19-CAR T) in the treatment of patients with refractory relapsed B cell acute lymphocyte leukemia(B-ALL).@*METHODS@#The efficacy and safety of CD19-CAR T cells in treatment of patients with refractory relapsed B-ALL from January 2015 to July 2017 in the Department of Hematology of Peking University Third Hospital were analyzed retrospectively.@*RESULTS@#A total of 10 patients were included in this analysis, all of which were consistent with the diagnosis of refractory relapsed B-ALL, and the immunophenotype of leukemia cells was CD19 positive. After treatment with CD19-CAR T cells, the overall response rate(ORR) on day 28 was 70%. Among them, 6 cases reached complete remission(CR), 1 case reached partial remission(PR). The rate of CR on day 90 was 30%.@*CONCLUSION@#CD19-CAR T cells are effective in the treatment of refractory relapsed B-ALL, and the adverse reactions are controllable.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Recidiva
/
Linfócitos B
/
Receptores de Antígenos de Linfócitos T
/
Linfócitos T
/
Leucemia de Células B
/
Doença Aguda
/
Estudos Retrospectivos
/
Imunoterapia Adotiva
/
Antígenos CD19
Tipo de estudo:
Estudo observacional
Limite:
Humanos
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS